— Know what they know.
Not Investment Advice

KPTI NASDAQ

Karyopharm Therapeutics Inc.
1W: -50.5% 1M: -55.2% 3M: -91.7% YTD: -88.8% 1Y: -87.1% 3Y: -96.1% 5Y: -99.1%
$0.80
-0.06 (-7.45%)
 
Weekly Expected Move ±20.4%
$0 $1 $1 $1 $1
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 33 · $18.2M mcap · 15M float · 8.60% daily turnover · Short 43% of daily vol

Cash Flow Trends

Operating Cash Flow
-$75M +40.9% ▲
Capital Expenditures
$0 +100.0% ▲
Free Cash Flow
-$75M +40.9% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$2M -120.0% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$124M-$165M-$143M-$76M-$196M
Depreciation & Amort.$789K$621K$530K$340K-$114K
Stock-Based Comp.$30M$35M$22M$18M$14M
Change in Working Capital-$23M-$20M$31M-$302K$28M
Other Non-Cash Items$8M-$294K-$3M-$70M$78M
Operating Cash Flow-$107M-$150M-$93M-$127M-$75M
— Investing Activities —
Capital Expenditures-$6M-$118K$0-$142K$0
Acquisitions (Net)$6M$104M$0$0$0
Investment Purchases-$45M-$226M-$159M-$59M$0
Investment Sales$193M$122M$167M$154M$43M
Other Investing-$6M-$104M$0$0$0
Investing Cash Flow$142M-$104M$8M$95M$43M
— Financing Activities —
Net Debt Issuance$60M$0$0$83M$21M
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$4M$4M$0-$43M$0
Financing Cash Flow$74M$194M$1M$42M$30M
Net Change in Cash$108M-$61M-$84M$10M-$2M
Cash End of Period$197M$137M$53M$63M$61M
Free Cash Flow-$113M-$150M-$93M-$128M-$75M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms